Corporate Introduction

May 2019

Contents

1. Evolution overview

Timelines and key milestones

Consistent record of reliability and adherence to quality standards

1936

Uquifa Incorporation

Uquifa was founded as a manufacturers of opiates and FDF to pharmacies.

Uquifa became a leading supplier to Spanish pharmacies.

1991–92

Takeover by HCH

Acquired by Holliday Chemical Holdings, a UK based chemical company.

Uquifa acquired Barisintex with its headquarters and facilities in Sant Celoni, widening production capability

1997–98

Acquisition of the Mexican site

Uquifa acquired a new chemical plant in Mexico from SKB. This acquisition established the 3 manufacturing locations which Uquifa operates today.

In 1998, Holliday Chemical Holdings was acquired by Yule Catto Plc.

2011–12

Acquired by Vivimed

Acquired by Vivimed Labs, a India based healthcare and specialty chemicals company.

Investments stepped up on manufacturing plants, product mix, and people.

2012–17

Focus on growth

Uquifa is now focused on pursuing growth through a mix of CDMO and API.

Stronger client mining, new product filings, compliance and operational excellence being focus areas.

2017–18

Soneas acquisition

Raised capital from OrbiMed Asia, a healthcare focused PE firm.

Soneas acquisition completed which brings phase 1–2 capability, new customer base, chemistry capabilities and greater coverage of the CDMO sector.

Global presence: a strategic advantage

A global platform that combines quality with competitiveness

What is Uquifa's core positioning ?

Originator and Generic customers require support for chemical intermediates and API production in both the development and commercial phases

Drug development

Uquifa's core positioning

Research phase	Development phases I, II and III	High-scale manufacturing for commercial phase	Marketing	Distribution and sales
Research requires highly skilled experts that supply research pipelines with novel and innovative molecules.	Development includes both synthetic, analytical, and regulatory/administrative services.	Production process requires both production capacity and industrial expertise.	Marketing has become increasingly important over the last several years as a means of differentiation and maximizing the revenue potential of a given therapeutic.	Distribution requires logistics and coverage networks. A robust sales force is also required to negotiate volume, discounts and promote products.

Drug manufacturing

Uquifa's core positioning

Building blocks	Intermediates	API	Formulation and production	Packaging
Building blocks are the basic chemical ingredients involved in chemical / API synthesis.	Substances resulting from the conversion of reactants into a product and that are used for the proceeding steps in a chemical reaction.	Technical expertise in the development and manufacturing of a wide range of APIs	APIs are mixed with excipients based on a specific formulation for drug delivery.	Drug packaging and distribution.

Facility overview

	Lliçà de Vall Spain	St Celoni Spain	Cuernavaca Mexico	Budapest Hungary
Capacity	140, 000 L	170, 000 L	180, 000 L	208, 000 L
Number of reactors	29 reactors	29 reactors	30 reactors	58 reactors
Last US FDA Inspection	September 2015	May 2017	July 2018	—
8c-GMP Approval	Yes	Yes	Yes	Yes
Korean FDA	June 2011	June 2011	June 2011	—
Japanese Certification	Yes	Yes	Yes	—
Pilot plant in site	Multipurpose	Multipurpose	Multipurpose	Multipurpose
Residues treatment on-site	Mercaptan incinerator, biological effluent treatment	Biological effluent treatment	Biological effluent treatment off-site	Catalytic incinerator, off-site waste treatment
Technical expertise	Sulphur chemistry, wiped film evaporation, hydrogenation, micronisation, sieving	Sulphur chemistry, roller compact unit, micronisation, sieving, lyophilisation	Nitration, hydrogenation, in-situ prep, chlorination	Optical resolutions, cryogenic and organometallic, high temperature, cyclopropanation, phosgenation (triphosgene), hydrogenations, halogenations, acid chloride preparations, carbene additions, diazotizations, Friedel-Crafts reactions, isomerizations, cyanations, carbonylation with CO

Uquifa Today

Financials

Sales of €130mn (2018)

Consistently Profitable

Employees

- 370 in Spain
- 150 in Mexico
- 170 in Hungary
- 50 in India

Manufacturing sites

- 3 US FDA Approved API Manufacturing Plants
- 4 Pilot Plants
- 1 Intermediates Manufacturing Site
- 1500MT of API manufactured in 2018
- 55-60 unique products manufactured every month

R&D Centers

- 5 Research and Development Centers
- Strong Scientific Expertise
- Infusing Proprietary Technology to bring additional value to our customers

Global Presence

- A strategic advantage that combines quality with competitiveness
- HQ is in Europe
- Manufacturing sites and R&D centers are in Europe and NA
- Purchasing offices are in India and China
- Sales offices are in Europe and US

Customer Base

- Global, with clients in more than 70 countries worldwide

2. API portfolio

API products

Therapeutic areas

Bulk API

Anti Ulcer

Antibiotic

Antifungal

Antiviral

Niche API

Antihistamine
Sedative
Hypnotic

Analgesic

Anti Hypertensive[10]

Mydiatric

Vasodilator

Analgesic / Narcotic

New API

Anti Depressant

Anti Convulsant

Anti Parkinsonian

Anti Ulcerative

Bone Resorption Inhibitor

Calcium Channel Blocker

Ethical API

Antiparasitic Agent (Veterinary)

Anthelmintic

Antihistamine
Antipsychotic
Anxiolytic

Skeletal Muscle Relaxants

Boehringer Ingelheim · Pfizer · EGIS · TEVA · SANDOZ · Mylan

NORMON · AET · STADA · Lannett · Actavis · SANOFI

Regulatory expertise

Highly trained regulatory experts at each site with experience in all major geographies

- Filing Experience in all major geographies
  - Over 50 Type II DMF's filed with the FDA
  - More than 150 active DMF's worldwide
- Over 25 valid Certificates of Suitability
- Many years of successful regulatory audits by different agencies

Dossier Registration : Capabilities

- Uquifa developed registration dossiers with in-house APIs and is well versed with EU filings and ANDAs for the USA
- Uquifa works with partners to develop the formulation, perform the bio-equivalency and files the dossier to obtain Marketing Authorizations
- Uquifa is willing to license either the dossier and/or the Marketing Authorization

Diversified product mix

DMFs and CEPs across 3 sites in Europe and North America

Cuernavaca Mexico

Albendazole
Benzydamine
Cinacalcet
Ciprofloxacine Base
Ciprofloxacine HCl CoS
Halofantrine
Ketoconazole CoS
Levofloxacine
Metformin CoS
Oxantel
Pantoprazole CoS
Pyrantel
Rabeprazole
Terbinafine
Tolterodine
Tropicamide
Zolpidem CoS
Apixaban
Bilastine
Brexpiprazole
Brivaracetam
Dabigatran
Edoxaban
Mirabegron
Mebendazole
Ricobendazole

Lliçà de Vall Spain

Clindamycin HCl CoS
Cyclopentolate
Erlotinib
Etofenamate CoS
Fluoxetine CoS
Ketorolac
Lamotrigine CoS
Omeprazole Base CoS
Omeprazole Mg
Omeprazole Na
Pantoprazole
Quetiapine
Pethidine CoS
Ranitidine CoS

Sant Celoni Spain

Allopurinol CoS
Acyclovir CoS
Bicalutamide
Cimetidine CoS
Ciprofloxacine
Clindamycin Phosphate CoS
Doxylamine Succinate CoS
Duloxetine
Esomeprazol Na
Esomeprazol Mg
Famotidine
Ketorolac
Lansoprazole CoS
Linezolid
Memantine
Nimodipine CoS
Nitrendipine
Omeprazole Pellets
Risedronate
Robenidine VET
Solifenacine Succinate
Tapentadol
Minocycline

Dossiers Spain

Omeprazole 20mg, 40mg caps
Pantoprazole 20mg, 40mg FCT
Duloxetine 30mg, 60mg caps
Linezolid 600mg FCT
Linezolid 2mg/ml 300ml bags
Erlotinib 100mg, 150mg tablets

3. CDMO: Infrastructure and capability

13

Why Uquifa for CDMO?

Protection

We protect your intellectual property

Quality

Strong quality system approved by regulators and customers

14

Expertise

Technical expertise in the development and manufacture of wide range of API's

Integration

Backward integration ensures cost efficient operations.
The location of our manufacturing base Is a source of risk mitigation for our customers.

Flexibility

Flexible and adaptable to fulfil your needs

CDMO platform

Evolving constantly

Based in Barcelona, Spain, we are one of the first API/ advanced intermediates manufacturing companies offering R&D and cGMP manufacturing across three continents.

Post Soneas acquisition, we also offer our manufacturing facilities in Budapest, Hungary.

Services include:

15

- Development of novel synthetic routes and optimisation of existing laboratory processes
- Scale-up from Laboratory to Pilot Plant
- Scale-up from Pilot Plant to commercial
- Optimising laboratory developed routes of synthesis to reduce isolation steps, improve yield, reduce batch production time and eliminate the use of toxic and/or dangerous reagents
- Transfer of commercial scale processes

Chemistry capabilities

- Grignard reactions & Organometallic Chemistry
- Fisher esterification & trans-esterification
- Chiral Synthesis, Chiral resolution and Asymmetric Synthesis
- Borane derivatives & coupling reactions
- Heck reactions
- Ozonolysis
- Halogenations, Nitrations and Sulphur Chemistry
- Hydrogenations (up to 5 bar) & reductions with reductive agents and different kind of hydrides
- Triphosgene reactions (industrial precursor for phosgene)
- Protection & de-protection Chemistry
- Solid phase reactions
- Crystallisation
- PSD expertise
- Polymorphism Studies
- Pellets manufacturing capability in Spain

Development and scale up capability

International R&D

Spain and Mexico R&D Lab

Custom synthesis, process improvement

- Capable of producing compounds from 1g to 1kg
- Small-scale glassware up to 20L glass reactors
- Make processes scalable, safe and environmentally friendly:
  - Reduces isolation steps
  - Improves yield
  - Minimizes batch production time
  - Eliminates use of toxic and/or dangerous reagents

Dedicated Analytical group for method development

- HPLC, GC-MS, IR, UV, TGA, DSC, PSD (Malvern Mastersizer and Air-Jet)

Spain and Mexico Pilot Plant

Scale-up and small scale production

- Producing 1kg to multi-kg quantities for Phase I, II and III clinical trials and for small scale commercial production
- Variety of vessel sizes and materials of construction

Installations are flexible allowing many combinations of reactors, filters and dryers

- Cryogenic capability
- Ozonolysis, hydrogenation and nitration

Qualified technicians run the plants under cGMP, on FDA approved sites

- The quality control systems in the PP are identical to those used for commercial production

Soneas enters Uquifa group

Our latest news

Recently, Uquifa acquired 100% of equity in Soneas, a Hungary based manufacturing of fine chemicals.

Soneas, leading central European custom and contract developer and manufacturer of fine chemicals for the pharma and other industries based in Budapest, Hungary.

Soneas has a high level of competency in NCE development as well as new technologies such as metal catalysis and heterocyclic chemistry and has capabilities for varied end usages which includes Neurology, Dermatology, Metathesis Catalysts, and others.

Acquisition of Soneas will allow it to expand faster into the CDMO sector, which accounts for 40% of the Uquifa sales. Broadens Uquifa's market offering in the CDMO space enhancing its ability now to undertake preclinical Phase I, II and III NCE project development.

Read more about our new relationship with Soneas

Synergies for Uquifa

Access

Access to Phase I & II development capabilities

Bolts on well to Uquifa's large scale GMP base.

Diversify

Diversified customer base and new markets like Japan

More markets to offer our enhanced technology toolbox

Leverage

Opportunity to leverage better the large scale KSM manufacturing site

The Tétényi site brings to our customer base a higher manufacturing capacity within the EU

Chemistries

- Optical resolutions
- Cryogenic and organometallic reactions
- High temperature reactions
- Cyclopropanation
- Phosgenation (triphosgene)
- Hydrogenations
- Halogenations
- Acid chloride preparations
- Carbene additions
- Diazotizations
- Friedel-Crafts reactions
- Isomerizations
- Cyanations
- Carbonylation with CO
- Cyclopentediene chemistry
- Palladium catalyzed carbonylation

20

4. Advantage Uquifa

Uquifa's advantage



Our contacts

C/ Mallorca 262, 3rd Floor
Barcelona, Spain, 08008

Phone: +34 934 674 810

www.uquifa.com

Sales Enquiries

info2@uquifa.com

SONEAS

Headquarters and Pilot Plant

Illatos út 33, Budapest, 1097-Hungary

+36 1 347 5060

info@soneas.com

soneas.com

Large Scale Manufacturing

Bányalég u. 47–59, Budapest, 1225-Hungary

+36 1 424 1111

info@soneas.com

soneas.com